Peptide Use Is Rising in Australia. Here's What You Need to Track If You're Taking the Risk

A lot of people are already injecting peptides they sourced from a research-chemical website, and almost none of them have a way to check what it is actually doing to their bloodwork while they do it. That is the real gap here, not whether TB-500 and BPC-157 work, which is a separate and genuinely uncertain question. This article is not making the case for using them. Biolume does not recommend either compound, and nothing here should be read as dosage guidance. It exists because the testing infrastructure around peptide use has not caught up to how widespread it already is, and somebody using these compounds without a doctor in the loop deserves a real answer to the question of what to actually monitor.

Both peptides are popular for recovery and tissue repair, circulating largely through research-chemical suppliers rather than regulated pharmacies. That distinction matters more than most people using them realise. A peptide bought this way has no guarantee of purity, dosage accuracy, or sterility, and the user has effectively opted out of the safety infrastructure that exists around approved therapeutics. None of that is a reason to panic. It is a reason to monitor.

What actually needs watching depends on the specific risk profile of the compound, but a few categories come up consistently in the available data and clinical commentary.

• Inflammatory markers (hsCRP). Both peptides are positioned as modulating inflammation, and a baseline-to-follow-up comparison is the only way to know if that is genuinely happening or just assumed.

• Liver function (ALT, AST, GGT). Anything entering the body via unregulated injection carries a non-trivial burden on metabolic clearance pathways, and liver enzymes are a sensitive early signal.

• Full blood count. Partly to catch anything unusual early, partly because injection-site and immune reactions are a documented risk with unregulated peptide sourcing.

• Kidney function (eGFR, creatinine). Worth adding for anyone using these compounds at higher doses or for extended periods.

None of this is about proving a peptide works. It is about knowing what your body is actually doing in response to something it did not encounter through a regulated, dosage-controlled pathway. A baseline test before starting, repeated periodically while using, gives you actual data rather than a subjective sense of feeling better or worse. That subjective sense is unreliable in both directions. People feel better on placebo. People also feel fine right up until a liver enzyme result says otherwise.

The honest position here is narrow and deliberately so. Biolume is not endorsing peptide use, and nothing in this article should be read as dosage guidance or a safety green light. If you are already using TB-500 or BPC-157, the markers above are the ones that matter, and they are not hard to access. Liver function, kidney function, full blood count, and hsCRP are all available through a standard Medicare-referred pathology request, and the same panel can be tracked over time through Biolume if you want a baseline and follow-up results sitting in one place without having to chase a new referral each time. Get it done through your GP, get it done through us, it does not matter which. What matters is that you are actually monitoring the risk instead of guessing at it.